GLP-1 receptor agonists slow gastric emptying, suppress appetite, and reduce caloric intake by design. Those same mechanisms sit upstream of iron homeostasis, which depends on dietary intake, gastric acid for solubilization, and duodenal absorption kinetics that gastric slowing can alter.
The published evidence is smaller and more mixed than the mechanistic story suggests. One pilot study found reduced iron absorption after semaglutide initiation. A separate, larger population study found the opposite association in a different patient group. Both are worth reading, and neither settles the question.
This article is a literature review for laboratory and research contexts. It does not describe a treatment protocol and is not medical advice. Research use only. Not for human or veterinary use.
- A 51-person semaglutide pilot measured a 13% median relative reduction in oral iron absorption after 10 weeks; it did not measure long-term anemia.
- A separate celiac-disease abstract reported iron-deficiency anemia in 5.4% of GLP-1 users versus 6.5% of non-users; it cannot establish a protective drug effect.
- Dietary intake, intestinal absorption, iron stores, and anemia are different endpoints. No study here establishes that an iron formulation treats a GLP-1-related effect.
Participants in pilot
Median absorption change
Anemia in separate celiac cohorts
The mechanistic case
Gastric emptying and acid-dependent absorption
Gastric acid helps solubilize non-heme ferric (Fe³+) iron. Reduction to ferrous (Fe²+) iron occurs at the intestinal brush border before uptake via DMT1. GLP-1 receptor agonists delay gastric emptying; whether this changes long-term iron status through altered delivery, intake, or both remains unresolved [2].
Reduced intake as a confound
GLP-1 agonists reduce caloric intake substantially, and dietary iron intake tracks with total food intake. A drop in iron status attributable to eating less food is a nutritional effect, not necessarily an absorption effect, and separating the two is a recurring problem in this literature.
What a before-and-after pilot study found
A 2025 pilot study in Diabetes, Obesity and Metabolism (Melis et al.) gave an oral iron absorption test — a single 350 mg ferrous fumarate capsule after a 12-hour fast — to 51 adults with type 2 diabetes before and 10 weeks after starting once-weekly semaglutide [1]. The median relative reduction in the test response was 13%, and 17.6% of participants (9 of 51) showed at least a 30% reduction from baseline. Long-term iron stores and anemia outcomes were not measured in this pilot [1].
A 2026 perspective review proposed that reduced dietary variety — particularly lower intake of iron-rich meat, fish, and seafood — might compound an absorption-level effect. These are proposed mechanisms, not established causal pathways [2].
What a larger population study found — in the opposite direction
A 2025 conference abstract from an observational comparison of people with celiac disease reported iron-deficiency anemia in 5.4% of GLP-1 users versus 6.5% of non-users [3]. It measured an association in a different population, not iron absorption before and after treatment. The abstract alone cannot establish whether the exposure caused the difference, and its authors called for further study.
Before/after oral iron test at 10 weeks
13% median reduction in test response
GLP-1 users versus non-users
5.4% versus 6.5% anemia
Short-term absorption is not the same outcome as diagnosed anemia. Neither design proves a class-wide effect.
This finding does not contradict the absorption-test result; it measures a different population, a different outcome, and cannot isolate mechanism from the underlying disease. But it is a direct counterexample to a simple “GLP-1 causes anemia” claim, and any review of this topic that omits it is incomplete.
Vitamin B12: a separate and more contested question
B12 deficiency is frequently discussed alongside iron in GLP-1 patients, but the two are mechanistically distinct and should not be pooled into one “anemia” narrative — iron deficiency produces microcytic anemia, B12 deficiency produces macrocytic anemia, and conflating them obscures which lab marker actually moved.
A direct semaglutide-to-B12-deficiency mechanism is not established by the evidence cited here; B12 deficiency is not identified as an adverse reaction in the cited product characteristics [4]. Reduced dietary intake and co-prescribed metformin are separate potential explanations. Long-term metformin exposure and B12 deficiency have been studied in a randomized trial [5]; that result should not be attributed to the GLP-1 receptor agonist.
What this literature does not establish
- That GLP-1 receptor agonists cause iron-deficiency anemia as a class effect. One pilot study found reduced absorption; a larger population study found reduced IDA risk in a different population. Neither is definitive, and they point in different directions.
- That reduced intake and altered absorption kinetics are separable in existing data. The pilot study measured absorption directly, but most other observations cannot distinguish “eating less iron” from “absorbing iron differently.”
- That B12 and iron deficiency in this population share one mechanism. The clinical evidence for a direct GLP-1–B12 mechanism is weaker than commonly stated in patient-facing sources, and metformin co-prescription is a significant confound.
- That any iron formulation reverses or prevents a GLP-1-associated effect. No study reviewed here tested that question, and no claim of that kind is made below.
Designing a study in this area
Match iron markers to compartment. Ferritin, transferrin saturation, and a direct absorption test (as in Melis et al.) answer different questions. An absorption test isolates the mechanism the mechanistic hypothesis actually predicts; a population-level anemia rate does not.
Control for intake and underlying disease. The celiac-disease finding shows why a disease-matched comparator matters — without one, a difference in outcomes can’t be assigned to the drug.
Separate B12 and iron endpoints. Report them as distinct outcomes with distinct reference ranges and distinct mechanistic hypotheses rather than a combined “anemia” endpoint.
Report dose and duration. The 2026 review identifies the need for better agent-specific and dose-response comparisons; do not transfer findings from semaglutide to all receptor agonists [2].
Iron sucrose and ferrous gluconate: a composition reference
Iron sucrose and ferrous gluconate are two distinct, well-characterized iron compounds relevant to any laboratory studying iron absorption, supplementation kinetics, or formulation chemistry — including in the GLP-1 context above.
| Property | Iron Sucrose | Ferrous Gluconate |
|---|---|---|
| CAS number | 8047-67-4 | 299-29-6 |
| PubChem CID | 91663255 | 23616740 |
| Composition | Colloidal iron(III)-hydroxide sucrose complex; not one discrete molecule | Iron(II) gluconate salt |
| Route in established clinical research | Parenteral | Oral formulations studied separately |
| ATC code | B03AB02 | B03AA03 |
Iron sucrose is a colloidal iron(III)-hydroxide sucrose complex, administered parenterally in clinical settings specifically because it bypasses the gastric-acid-dependent absorption step described above — a mechanistic contrast point for anyone modeling oral versus parenteral iron kinetics.
Ferrous gluconate is an iron(II) salt relevant to oral-absorption models. The Melis et al. study tested ferrous fumarate, not ferrous gluconate, and did not compare either with iron sucrose [1]. These materials are not interchangeable experimental controls.
4AminoLabs lists iron sucrose (100 mg/mL) and ferrous gluconate (35 mg/mL) in its research-only Iron Complex. This formulation was not evaluated in either GLP-1 study discussed above.
Research use only. All products supplied by 4AminoLabs are intended strictly for laboratory research. They are not drugs, dietary supplements, food, cosmetics, or veterinary products, and are not intended to diagnose, treat, cure, or prevent any disease.
Frequently asked questions
Do GLP-1 receptor agonists cause anemia?
The evidence is mixed. A 2025 pilot study found reduced iron absorption after semaglutide initiation, while a larger population study found reduced iron-deficiency-anemia risk among GLP-1 users with celiac disease. A causal, dose-dependent effect has not been established.
What did the semaglutide iron absorption study actually measure?
A 2025 pilot study gave 51 patients an oral iron absorption test before and 10 weeks after starting semaglutide. Median absorption fell 13 percent, with 17.6 percent of patients showing a reduction of 30 percent or more.
Is the GLP-1-B12 connection well established?
Less than commonly stated. The approved semaglutide product information does not list B12 deficiency as an adverse reaction, and metformin co-prescription is a separately documented cause of B12 deficiency in this population.
What is the difference between iron sucrose and ferrous gluconate?
Iron sucrose is a colloidal Fe3+-sucrose complex used parenterally, bypassing gastric absorption. Ferrous gluconate is an Fe2+ salt relevant to oral-absorption research, since it does not require gastric reduction before uptake.
Does an iron supplement address a GLP-1 drug effect?
That has not been studied or established. This article and the referenced product are for research use; nothing here is a treatment recommendation.
References
- Melis P, et al. The effect of semaglutide on intestinal iron absorption in patients with type 2 diabetes mellitus—a pilot study. Diabetes Obes Metab. 2025;27:3542–3545. DOI: 10.1111/dom.16368.
- Infante M, et al. Ironing Out Possible Micronutrient Deficiencies Associated with Incretin Receptor Agonist-Based Therapies: Proposed Practical Strategies to Prevent and Manage Iron Deficiency. Nutrients. 2026;18(13):2038. A perspective review, not a clinical trial.
- Ghobrial J, et al. S793 Reduced Risk of Iron Deficiency Anemia With GLP-1 Use in Celiac Disease Patients. Am J Gastroenterol. 2025;120(10S2):S170. Conference abstract, not a full peer-reviewed report.
- Wegovy (semaglutide) 2.4 mg Summary of Product Characteristics. Electronic Medicines Compendium, adverse reactions section. Absence from the listed adverse reactions does not prove absence of an effect.
- de Jager J, et al. Long term treatment with metformin in patients with type 2 diabetes and risk of vitamin B-12 deficiency: randomised placebo controlled trial. BMJ. 2010;340:c2181.
Research use only. All products supplied by 4AminoLabs are intended strictly for laboratory research. They are not drugs, dietary supplements, food, cosmetics, or veterinary products, and are not for human or animal consumption.